Showing 49 to 60 of 171 results
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Progress
44% Bias Score
Three-Drug Combo Doubles Survival Time for Aggressive Colorectal Cancer
A late-stage trial revealed that a three-drug combination—including a standard chemotherapy drug, cetuximab, and Braftovi—doubled the survival time for colorectal cancer patients with the BRAF V600E mutation to approximately 30 months, compared to 15 months with standard chemotherapy, offering a sig...
Three-Drug Combo Doubles Survival Time for Aggressive Colorectal Cancer
A late-stage trial revealed that a three-drug combination—including a standard chemotherapy drug, cetuximab, and Braftovi—doubled the survival time for colorectal cancer patients with the BRAF V600E mutation to approximately 30 months, compared to 15 months with standard chemotherapy, offering a sig...
Progress
44% Bias Score
Misdiagnosis Leads to Terminal Melanoma in British Mother
A 32-year-old British mother, Katie Cooper, was misdiagnosed with a virus after experiencing pain, leading to a terminal melanoma diagnosis after the cancer spread to her bones, spine, liver, lungs, abdominal wall, and ovaries; highlighting the importance of persistent medical attention.
Misdiagnosis Leads to Terminal Melanoma in British Mother
A 32-year-old British mother, Katie Cooper, was misdiagnosed with a virus after experiencing pain, leading to a terminal melanoma diagnosis after the cancer spread to her bones, spine, liver, lungs, abdominal wall, and ovaries; highlighting the importance of persistent medical attention.
Progress
44% Bias Score
NHS Elective Operation Cancellations More Than Double in a Decade
In England, 23% of 85,400 cancelled elective NHS operations in 2024-25 weren't rescheduled within 28 days, a more than doubling of breaches since 2015-16 (from 7% to 23%), with University Hospitals of Leicester reporting the highest number (942).
NHS Elective Operation Cancellations More Than Double in a Decade
In England, 23% of 85,400 cancelled elective NHS operations in 2024-25 weren't rescheduled within 28 days, a more than doubling of breaches since 2015-16 (from 7% to 23%), with University Hospitals of Leicester reporting the highest number (942).
Progress
44% Bias Score
Athens Hospital Concert Brightens Children's Day
A one-hour piano concert, part of the Piano City Athens festival and held in collaboration with the 'Elpida' Association, brought joy and respite to children in the Oncology ward of Agia Sophia Children's Hospital in Athens, Greece, on May 2024, offering a therapeutic distraction from their illnesse...
Athens Hospital Concert Brightens Children's Day
A one-hour piano concert, part of the Piano City Athens festival and held in collaboration with the 'Elpida' Association, brought joy and respite to children in the Oncology ward of Agia Sophia Children's Hospital in Athens, Greece, on May 2024, offering a therapeutic distraction from their illnesse...
Progress
16% Bias Score
ChemoID Test Significantly Improves Outcomes for Platinum-Resistant Ovarian Cancer
A phase 3 clinical trial published in Nature Partner Journal "Precision Oncology" demonstrates that the ChemoID test, analyzing tumor stem cells to guide chemotherapy selection, significantly improves response rates (50% vs 5%) and progression-free survival (11 months vs 3 months) in patients with p...
ChemoID Test Significantly Improves Outcomes for Platinum-Resistant Ovarian Cancer
A phase 3 clinical trial published in Nature Partner Journal "Precision Oncology" demonstrates that the ChemoID test, analyzing tumor stem cells to guide chemotherapy selection, significantly improves response rates (50% vs 5%) and progression-free survival (11 months vs 3 months) in patients with p...
Progress
48% Bias Score
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Progress
44% Bias Score
AI Test Could Slash Prostate Cancer Deaths by Half
A new AI test identifies a biomarker in high-risk prostate cancer patients, enabling targeted abiraterone treatment; reducing the five-year death risk by 47 percent in those with the biomarker, potentially benefiting 2,100 men annually in England.
AI Test Could Slash Prostate Cancer Deaths by Half
A new AI test identifies a biomarker in high-risk prostate cancer patients, enabling targeted abiraterone treatment; reducing the five-year death risk by 47 percent in those with the biomarker, potentially benefiting 2,100 men annually in England.
Progress
48% Bias Score
New Drug Shows Promise in Treating Lung Cancer in Non-Smokers
A clinical trial of the drug zongertinib shows promise in treating HER2-mutated lung cancer in non-smokers, with 70% of participants experiencing tumor shrinkage; this offers hope for a previously difficult-to-treat cancer subtype that affects approximately 6,000 non-smokers annually in Spain.
New Drug Shows Promise in Treating Lung Cancer in Non-Smokers
A clinical trial of the drug zongertinib shows promise in treating HER2-mutated lung cancer in non-smokers, with 70% of participants experiencing tumor shrinkage; this offers hope for a previously difficult-to-treat cancer subtype that affects approximately 6,000 non-smokers annually in Spain.
Progress
44% Bias Score
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
Progress
40% Bias Score
Ultra-Rapid Brain Tumor Test a "Game Changer", Improves Diagnosis Time to Hours
A new "ultra-rapid" genetic test for brain tumors, developed at the University of Nottingham, diagnoses tumor types in hours instead of weeks, improving treatment and reducing patient anxiety; it has been successfully used in 50 operations at Nottingham University Hospitals NHS Trust with a 100% suc...
Ultra-Rapid Brain Tumor Test a "Game Changer", Improves Diagnosis Time to Hours
A new "ultra-rapid" genetic test for brain tumors, developed at the University of Nottingham, diagnoses tumor types in hours instead of weeks, improving treatment and reducing patient anxiety; it has been successfully used in 50 operations at Nottingham University Hospitals NHS Trust with a 100% suc...
Progress
44% Bias Score
Man Accused of Stealing from Daughter's Funeral GoFundMe
Mark Davis, 51, from Newport, is accused of stealing £4,059.27 from a GoFundMe account set up for his late daughter India Davis's funeral, who died aged 24 from ovarian cancer in 2022. He denies the charge and will stand trial in April 2024.
Man Accused of Stealing from Daughter's Funeral GoFundMe
Mark Davis, 51, from Newport, is accused of stealing £4,059.27 from a GoFundMe account set up for his late daughter India Davis's funeral, who died aged 24 from ovarian cancer in 2022. He denies the charge and will stand trial in April 2024.
Progress
44% Bias Score
Showing 49 to 60 of 171 results